[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jilin University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100638977","two-different-endoscopic-treatments-for-rectal-neuroendocrine-neoplasms-100638977",false,"NCT07612748","Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms","Retrospective Comparative Study of Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms","Inclusion Criteria:\n\n* Patients undergoing endoscopic treatment for rectal neuroendocrine neoplasms.\n* Lesion diameter less than 2 cm.\n* Preoperative auxiliary examinations indicating no peripheral lymph node or distant metastasis.\n* Endoscopic surgical approach limited to ESD or EPMR.\n\nExclusion Criteria:\n\n* Use of non-ESD or non-EPMR endoscopic techniques, such as ligation-assisted resection or Endoscopic Mucosal Resection (EMR).\n* Presence of other conditions deemed by the investigator to be unsuitable for participation in this study.\n* Patient or family refusal to participate.","ALL","18 Years",{"count":19,"type":20},483,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim is to compare the safety and efficacy of endoscopic submucosal dissection (ESD) versus endoscopic partial muscle resection（ EPMR） for the treatment of rectal neuroendocrine neoplasms (R-NENs), thereby providing guidance for optimizing therapeutic strategies. The investigators retrospectively analyzed consecutive patients with R-NENs who underwent endoscopic resection at our center between January 2020 and February 2026. Patients were assigned to either the ESD group or the EPMR group. Baseline characteristics and perioperative outcomes were compared, including the number of lesions, maximum lesion diameter, single-lesion procedure time, postoperative complications, positive margin rate, pathological staging, lymphovascular invasion, and the need for additional therapies.",[26,27,28],"Rectal Neuroendocrine Tumors","ESD","EPMR",[27,28],"RECRUITING","2026-05-31",{"date":33,"type":34},"2026-06-03","ACTUAL",{"date":36,"type":34},"2026-06-01",{"date":38,"type":20},"2027-12-01",{"name":40,"class":41},"Jilin University","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100507796","anti-coagulation-on-left-ventricular-thrombus-after-st-segment-elevation-myocardial-infarction-100507796","NCT05892042","Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","ACTonLVT","Inclusion Criteria:\n\nEstablished ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.\n\nOngoing treatment with dual anti-platelet therapy according to ESC\u002FAHA guidelines at the time of randomization\n\nExclusion Criteria:\n\nClinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT.\n\nAny contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent","80 Years",{"count":53,"type":20},320,[23],"Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction",[57,58],"ST-segment Elevation Myocardial Infarction (STEMI)","Left Ventricular Thrombus",[60],"STEMI, LVT, Anticoagulation","2026-05-27",{"date":36,"type":34},{"date":64,"type":34},"2023-05-01",{"date":66,"type":20},"2026-12-01",{"name":40,"class":41},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":68},"100612466","distribution-characteristics-of-helicobacter-pylori-100612466","NCT07253948","Distribution Characteristics of Helicobacter Pylori","Distribution Characteristics of Helicobacter Pylori in Different Gastritis and Early Gastric Cancer States Using Immunohistochemical Staining","Inclusion Criteria:\n\n* age 18-80 years\n* received H. pylori immunohistochemical testing at our center and tested positive.\n\nExclusion Criteria:\n\n* biopsies not collected from both the greater and lesser curvatures of the gastric antrum and body\n* history of stomach surgery\n* suspected autoimmune gastritis under endoscopy\n* liver cirrhosis\n* severe comorbidities such as advanced cancer or renal failure\n* advanced gastric cancer or gastric lymphoma",{"count":77,"type":20},231,"OBSERVATIONAL","This study aimed to analyze the distribution characteristics of Helicobacter pylori（H. pylori） in varying stages of atrophic gastritis and early gastric cancer using immunohistochemical staining, with the goal of providing guidance for the early screening of gastric cancer.\n\nA retrospective analysis was conducted on gastric biopsy cases that underwent H. pylori immunohistochemical staining at our center from March 1, 2023, to August 15, 2025. Cases were classified into non-atrophic and atrophic groups based on the presence or absence of gastric atrophy. All cases were further divided into non-open and open atrophy groups and additionally into early gastric cancer and non-cancer groups. The distribution of H. pylori across subgroups was compared, and multivariate analyses were performed to identify risk factors associated with the development of early gastric cancer.",[81,82],"Helicobacter Pylori","Early Gastric Cancer",[84,85,86,87],"Helicobacter pylori","Immunohistochemical staining","Atrophic gastritis","Early gastric cancer screening","2025-11-26",{"date":90,"type":34},"2025-11-28",{"date":92,"type":34},"2025-10-22",{"date":94,"type":20},"2025-12-31",{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":68},"100551005","efficacy-of-upadacitinib-after-necs-in-vitiligo-100551005","NCT06454461","Efficacy of Upadacitinib After NECS in Vitiligo","Efficacy of Upadacitinib After Autologous Non-cultured Epidermal Cell Suspension Transplantation in Vitiligo Participants -- a Pilot, Random, Observer Blinded, Comparative Study","Inclusion Criteria:\n\n1. Participants who can sign the informed consent.\n2. Participants aged 18-60 years (both men and women) at the time of signing the informed consent.\n3. Non-segmented vitiligo\n4. Vitiligo affected area should meet the following two criteria:\n\n(1) containing the target area (relatively flat vitiligo lesions except of the hands and feet, perineum, lips, joints, perianal); (2) total BSA involvement ≤30% 5. Clinically stable for more than one year (stable refers to the original lesion no longer expanding and no new lesions appearing).\n\n6\\. All fertile women had to be willing to use at least one highly effective method of contraception from the time they signed informed consent through the final follow-up visit.\n\n7\\. Participants must be willing and able to adhere to scheduled visits and scheduled treatments, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Any active skin lesions (e.g. psoriasis, dermatitis, skin ulceration, etc.) or skin infections (bacterial, fungal, viral, etc.) which may interfere with the assessment of vitiligo at screening.\n2. Participants had a clinically significant infection (requiring hospitalization and parenteral treatment with antibiotics, antiviral agents, or antifungal agents for more than 3 days) within one month of the screening period or an active infection for which they were receiving treatment during the screening period.\n3. Infected with HBV or HCV or HIV or syphilis.\n4. Participants had active Tuberculosis or were receiving anti-Tuberculosis treatment, or had received anti-Tuberculosis treatment within 1 year.\n5. Hepatic dysfunction (Total bilirubin ≥ 2 × ULN, AST≥2 × ULN, ALT ≥ 2 × ULN) at screening.\n6. Renal impairment ( eGFR of \\\u003C45 mL\u002Fmin or receiving dialysis) at screening\n7. Participants with malignancy or with a history of malignancy other than adequately treated or resected nonmetastatic basal cell carcinoma or squamous cell carcinoma.\n8. Participants with current thyroid disease or undergoing thyroid replacement therapy.\n9. Participants with a history of mental illness, such as anxiety or depression, who were assessed by the investigator to be unfit to participate in the study.\n10. Pregnant or lactating female participants.\n11. Participants who received any laser or phototherapy for vitiligo within 4 weeks before baseline.\n12. Participants who received oral or systemic medications (e.g., glucocorticoids, cyclosporine, methotrexate, tacrolimus, Chinese medicine, etc.) aimed at controlling\u002Fimproving vitiligo symptoms within 4 weeks before baseline.\n13. Participants who had received JAK inhibitor therapy (including, but not limited to Ruxolitinib, Tofacitinib, Baricitinib, Upadacinib, etc.) within 12 weeks or 5 half-lives before baseline, whichever was longer.\n14. Participants who had used any biologic agent within 12 weeks or 5 half-lives before baseline, whichever was longer.\n15. Participants who had been enrolled in another intervention clinical trial within 4 weeks before the baseline visit or who were within 5 half-lives of the last dose of the intervention drug at baseline.\n16. Any other condition that the investigator considered might render the subject ineligible for inclusion in the study.","60 Years",{"count":105,"type":20},60,[23],"The goal of this clinical trial is to investigate the efficacy of upadacitinib after NECS in participants with vitiligo. The main question it aims to answer is: whether the short time use of upadacitinib after NECS will improve NECS efficacy. Participants in the experimental group will receive upadacitinib after NECS, while Participants in the control group will receive NECS only.",[109],"Vitiligo","2024-12-25",{"date":112,"type":34},"2024-12-27",{"date":114,"type":34},"2024-12-04",{"date":116,"type":20},"2029-06-01",{"name":40,"class":41},""]